REGENXBIO, Inc. (RGNX)
12.72
-0.52
(-3.93%)
USD |
NASDAQ |
Dec 09, 16:00
12.73
+0.01
(+0.08%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 643.93M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 25.07% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.024 |
| Price to Book Value | 3.988 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.661 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 89.37% |
Profile
| REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD. |
| URL | http://www.regenxbio.com |
| Investor Relations URL | http://ir.regenxbio.com/ |
| HQ State/Province | Maryland |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 12, 2026 (est.) |
| Last Earnings Release | Nov. 06, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD. |
| URL | http://www.regenxbio.com |
| Investor Relations URL | http://ir.regenxbio.com/ |
| HQ State/Province | Maryland |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 12, 2026 (est.) |
| Last Earnings Release | Nov. 06, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |